They are not the same thing, and mixing them up is one of the most consequential vocabulary errors in this field.

Progesterone is one specific molecule, chemically identical to what the ovary secretes after ovulation. Progestin, or progestogen, is an umbrella term for any molecule that acts on the progesterone receptor; most progestins are synthetic and structurally derived either from testosterone, like norethindrone and levonorgestrel, or from progesterone or spironolactone, like medroxyprogesterone acetate, dydrogesterone, and drospirenone. These molecules bind other hormone receptors differently than progesterone does, which is why they don't behave identically in the body, and treating them as interchangeable is a major source of public confusion about hormone therapy.

What to know about this answer

This isn't really a debate about facts, everyone in the field agrees progesterone and progestins are chemically distinct, the disagreement is about how much that distinction should change real-world prescribing and public communication.

What the research shows, and which source each finding rests on

Progesterone is one specific molecule identical to what the corpus luteum secretes; progestin/progestogen is an umbrella term for any molecule acting on the progesterone receptor, most of which are synthetic and structurally derived either from testosterone (norethindrone, levonorgestrel) or from progesterone/spironolactone (medroxyprogesterone acetate, dydrogesterone, drospirenone)

E[1]

Many progestins also bind androgen, glucocorticoid, or mineralocorticoid receptors to varying degrees, a pattern progesterone itself does not share in the same way

E[2]

Large observational datasets show the choice of progestogen is associated with different breast cancer risk, with micronized progesterone and dydrogesterone at the more favorable end and other progestins at the less favorable end

C[3]C[4]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

The distinction is mostly semantic for many clinical purposes

Older convention in general medical language, where progestin is used loosely to cover both

For decades, clinical shorthand used progestin or even progesterone interchangeably to mean whatever is added to estrogen therapy to protect the uterus, since for that specific purpose many progestins and progesterone both work, even though the molecules differ.

E[1]

The distinction has real, safety-relevant consequences

Multiple clinicians in the field, and the observational breast cancer data

Large observational studies show the choice of progestogen is associated with meaningfully different breast cancer and clotting risk, with micronized progesterone and dydrogesterone at the favorable end. One clinician put the underlying confusion bluntly: doctors calling a levonorgestrel IUD the progesterone IUD when there's no progesterone anywhere in the vicinity is exactly the kind of conflation that keeps women from understanding what they're actually taking.

C[3]C[4]

What would settle it: The chemical distinction itself is already settled; what remains genuinely open is a randomized trial comparing progestogens with breast cancer as an endpoint, which the field expects will almost certainly never be run given the required sample size and duration.

What is really going on here

  1. When someone says progesterone, do they mean the specific molecule, or are they using it loosely to mean any progestin?
  2. If my IUD or pill is described as containing progesterone, is that accurate, or does it actually contain a progestin like levonorgestrel?
  3. Is a safety or side-effect claim about progesterone actually about micronized progesterone specifically, or about a different progestin entirely?

Questions for your doctor

  1. Which specific molecule, progesterone or a named progestin, is in the product you're recommending for me?
  2. If I'm currently on a progestin, which one, and how does it differ from micronized progesterone?
  3. Does the specific progestogen I'm on affect my breast cancer or blood clot risk differently than progesterone would?
  4. If I have a levonorgestrel IUD, is that providing what I need for endometrial protection alongside estrogen therapy?

Questions with no answer yet

Does the favorable breast cancer signal for micronized progesterone reflect a genuine biological difference from other progestins, or partly reflect that the women prescribed it were healthier or better informed to begin with?

Partly studied

What is known: Large observational datasets show micronized progesterone and dydrogesterone at the more favorable end of breast cancer risk and other progestins at the less favorable end, but every one of these studies is observational, and this debate is expected to remain unresolved at the highest evidence level because a randomized trial with breast cancer as an endpoint would require a prohibitive sample size and duration.

What would test it: A randomized trial comparing progestogens with breast cancer as the primary endpoint; the field expects this will almost certainly never be run.

Do the receptor differences between progesterone and various progestins, such as androgen, glucocorticoid, or mineralocorticoid binding, actually explain the observed differences in breast cancer and clotting risk, or are those receptor differences and the risk differences simply correlated without a demonstrated causal link?

Partly studied

What is known: The differing receptor-binding profiles of progesterone versus various progestins are directly documented pharmacology; whether that receptor-binding pattern is the actual mechanism behind the observed differences in breast cancer or clotting outcomes has not been isolated in a controlled study.

What would test it: A mechanistic study directly linking a specific progestin's receptor-binding profile to a measured clinical outcome difference, controlling for other variables.

Sources

  1. 1.Pharmacology of estrogens and progestogens: influence of different routes of administration.Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8 Suppl 1:3-63. · Review, opinion or mechanism
  2. 2.Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.Stanczyk FZ, Hapgood JP, Winer S, Mishell DR. Progestogens used in postmenopausal hormone therapy. Endocr Rev 2013;34(2):171-208. · Review, opinion or mechanism
  3. 3.Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107(1):103-111. · Observational study
  4. 4.Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases.Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ 2020;371:m3873. · Observational study

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides